Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Oct;7(5):237-251.
doi: 10.1177/2040620716657994. Epub 2016 Jul 15.

Current developments in molecular monitoring in chronic myeloid leukemia

Justine Ellen Marum  1 , Susan Branford  1
Affiliations
Review

Current developments in molecular monitoring in chronic myeloid leukemia

Justine Ellen Marum et al. Ther Adv Hematol. 2016 Oct.

Abstract

Molecular monitoring plays an essential role in the clinical management of chronic myeloid leukemia (CML) patients, and now guides clinical decision making. Quantitative reverse-transcriptase-polymerase-chain-reaction (qRT-PCR) assessment of BCR-ABL1 transcript levels has become the standard of care protocol in CML. However, further developments are required to assess leukemic burden more efficiently, monitor minimal residual disease (MRD), detect mutations that drive resistance to tyrosine kinase inhibitor (TKI) therapy and identify predictors of response to TKI therapy. Cartridge-based BCR-ABL1 quantitation, digital PCR and next generation sequencing are examples of technologies which are currently being explored, evaluated and translated into the clinic. Here we review the emerging molecular methods/technologies currently being developed to advance molecular monitoring in CML.

Keywords: BCR-ABL1; Next-generation sequencing; chronic myeloid leukemia; digital PCR; minimal residual disease; molecular monitoring; qRT-PCR; resistance mutations.

PubMed Disclaimer

Conflict of interest statement

SB: Consultant to Cepheid, Advisory Board Member for Qiagen and Novartis. Honoraria and research funding from Novartis. Honoraria from Bristol Myers-Squibb. Research funding from Ariad. JM has no conflict of interest to declare.

References

    1. Alikian M., Ellery P., Forbes M., Gerrard G., Kasperaviciute D., Sosinsky A., et al. (2016) Next-generation sequencing-assisted DNA-based digital PCR for a personalized approach to the detection and quantification of residual disease in chronic myeloid leukemia patients. J Mol Diagn JMD 18: 176–189. - PubMed
    1. Annala M., Parker B., Zhang W., Nykter M. (2013) Fusion genes and their discovery using high throughput sequencing. Cancer Lett 340: 192–200. - PMC - PubMed
    1. Baccarani M., Cortes J., Pane F., Niederwieser D., Saglio G., Apperley J., et al. (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27: 6041–6051. - PMC - PubMed
    1. Baccarani M., Deininger M., Rosti G., Hochhaus A., Soverini S., Apperley J., et al. (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122: 872–884. - PMC - PubMed
    1. Bartley P., Latham S., Budgen B., Ross D., Hughes E., Branford S., et al. (2015) A DNA real-time quantitative pcr method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia. J Mol Diagn JMD 17: 185–192. - PubMed

LinkOut - more resources